New dual agonist candidate challenges Wegovy’s lead while eyeing mash market
Survodutide is matching the strongest semaglutide pill data on weight loss – and it is going after liver disease at the same time.
Boehringer Ingelheim announced that its dual glucagon/GLP‑1 receptor agonist survodutide (BI 456906) produced sustained average weight loss of up to 16.6 percent after 76 weeks in the Phase III SYNCHRONIZE‑1 trial in adults with obesity or overweight without type 2 diabetes, versus 3.2 percent on placebo, using the efficacy estimand (p<0.0001).
According to the company, 85.1 percent of adults on survodutide achieved at least 5 percent weight loss after 76 weeks, versus 38.8 percent on placebo.
An initial analysis said most of that loss came from fat rather than muscle, with lean mass “contributing only a small proportion of total weight.”
Boehringer Ingelheim also reported a statistically significant reduction in waist circumference versus placebo after 76 weeks, calling it a marker closely linked to visceral fat and cardiometabolic risk.
Full Phase III data are due at the American Diabetes Association’s 2026 Scientific Sessions.
Those topline numbers put survodutide in direct comparison with semaglutide, the current GLP‑1 benchmark.
A Cureus review of the Oral Semaglutide in Adults with Overweight or Obesity (OASIS) trials reported that once‑daily oral semaglutide 50 mg cut body weight by a mean 15.1 percent versus 2.4 percent with placebo in OASIS 1 over 68 weeks, 14.3 percent versus 1.3 percent in OASIS 2, and 13.6 percent versus 2.2 percent in OASIS 4, all with highly significant p values.
The same review noted that these higher oral doses underpinned the approval of oral Wegovy for chronic weight management, after earlier lower oral doses for diabetes (Rybelsus) and injectable formulations (Ozempic, Wegovy) had already established the class.
On responder rates, SYNCHRONIZE‑1 and OASIS look broadly aligned.
Boehringer Ingelheim reported that 85.1 percent of survodutide‑treated adults reached at least 5 percent weight loss at 76 weeks versus 38.8 percent on placebo.
According to the Cureus analysis, 85 percent of participants in OASIS 1 receiving oral semaglutide 50 mg achieved at least 5 percent loss at week 68 compared with 26 percent on placebo, and more than two‑thirds lost at least 10 percent, more than half at least 15 percent, and about one‑third at least 20 percent.
In OASIS 2, investigators reported that 84.3 percent of adults on oral semaglutide 50 mg achieved at least 5 percent weight loss versus 17.2 percent on placebo, with higher proportions on semaglutide also hitting 10 percent, 15 percent and 20 percent thresholds.
A comparative table compiled from OASIS 1, 2 and 4 showed estimated mean weight changes of 15.1 percent, 14.3 percent and 13.6 percent with oral semaglutide, versus 2.4 percent, 1.3 percent and 2.2 percent with placebo, and ≥5 percent loss rates of roughly 79 percent–85 percent on treatment against 17 percent–31 percent on placebo.
Semaglutide’s metabolic effects are already well described.
As per the Cureus review, the OASIS programme demonstrated favourable changes versus placebo in body mass index, absolute body weight, abdominal circumference, blood pressure, HbA1c, fasting glucose, fasting serum insulin, fasting lipid profiles and high‑sensitivity C‑reactive protein.
In OASIS 2, nearly three‑quarters of participants with type 2 diabetes at baseline who received oral semaglutide had reverted to either prediabetes or normoglycaemia by week 68, while only one patient on placebo had reverted to prediabetes.
The same review reported that oral Wegovy reduces major adverse cardiovascular events in patients with diabetes and documented coronary artery disease, chronic kidney disease or both, and that semaglutide is distributed as Rybelsus, Ozempic and Wegovy with route‑ and dose‑specific indications for type 2 diabetes and obesity.
Survodutide tries to add something different on top of GLP‑1‑class weight loss.
Boehringer Ingelheim describes it as a dual glucagon/GLP‑1 receptor agonist that “has the potential to address obesity while also supporting liver function, a key regulator of metabolic health.”
The company links the waist‑circumference reduction in SYNCHRONIZE‑1 to effects on visceral fat, noting that excess visceral fat, particularly abdominal, is a known contributor to metabolic dysfunction and closely connected to impaired liver function.
According to Boehringer Ingelheim, survodutide’s GLP‑1 agonism decreases appetite and increases fullness and satiety, while its glucagon agonism “is thought to directly act on the liver to reduce hepatic fat, regulate metabolic function, resolve inflammation, and improve fibrosis.”
The Obesity Medicine Association places survodutide within a broader surge of agents that target both weight and steatotic liver disease.
Its review of upcoming weight‑loss medications reported that survodutide completed separate Phase II trials in individuals with obesity and in those with biopsy‑confirmed metabolic dysfunction‑associated steatohepatitis (MASH).
In a 46‑week obesity trial, mean weight loss reached 14.9 percent at the highest dose, while in the MASH trial, improvement in MASH ranged from 43 percent to 62 percent depending on dose, with significant reductions in liver fat.
The same source noted that glucagon/GLP‑1 dual agonists, including mazdutide and survodutide, represent a way to target both weight and cardiometabolic health, given that glucagon receptors are mainly expressed in the liver.
Boehringer Ingelheim is already running a dedicated liver‑disease programme.
The company said survodutide is being studied in two global Phase III trials, LIVERAGE and LIVERAGE‑Cirrhosis, in adults with MASH and fibrosis stages 2 or 3 and in those with compensated MASH cirrhosis (fibrosis stage 4), alongside a comprehensive Phase III obesity programme.
It stated that survodutide “has the potential to be the first global glucagon/GLP‑1 dual agonist to help the more than 1 billion people living with obesity and MASH.”
Safety is the other pillar of the comparison.
Boehringer Ingelheim said that, as expected with GLP‑1‑based therapies, participants in SYNCHRONIZE‑1 experienced gastrointestinal events, with discontinuations occurring more frequently during dose escalation; it characterised these events as mild to moderate and temporary, and reported no new safety concerns outside what is expected for the GLP-1 class.
The Cureus review found a similar pattern for oral semaglutide in the OASIS trials: high overall rates of adverse events in both active and placebo arms, dominated by gastrointestinal symptoms such as nausea, constipation, diarrhoea and vomiting, mostly mild to moderate, concentrated during dose titration, and rarely leading to permanent discontinuation, with very low rates of hypoglycaemia.
